Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467458 | 0.84 | NPY5R (0.42) | KMT2AALDH1A1KDM4EGAALMNA | |
| SCHEMBL152894 | 0.76 | KDM4E (0.41) | ALDH1A1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL9780121 | 0.74 | KMT2A (0.44) | KMT2AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL118747 | 0.73 | DRD4 (0.45) | MAOAMAOBTHRBDRD4TSHR | |
| SCHEMBL30276323 | 0.73 | KMT2A (0.46) | KMT2AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL29395306 | 0.72 | MAOB (0.60) | KMT2AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL132696 | 0.72 | MAOB (0.60) | KMT2AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL29799860 | 0.72 | MAOB (0.60) | KMT2AMAOAMAOBALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL572068 | 0.70 | MAOB (0.58) | KMT2AMAOAMAOBALDH1A1KDM4E | |
| Methane SCHEMBL29238124 | 0.70 | MAOB (0.58) | KMT2AMAOAMAOBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| EP-2079736-B1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2476679-B1 | Substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-9133097-B2 | Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-20150051207-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8741967-B2 | Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2476679-A2 | Substituted triazoles useful as AXL inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110098317-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2079736-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009076598-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008083356-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | AXL, TYRO3, MERTK | KMT2A 2917/4885MAOA 1587/4885MAOB 1404/4885 |
| US-20150051207-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | SGMS1, SPHK1, S1PR3 | KMT2A 4126/4885MAOA 4453/4885MAOB 3439/4885 |
| US-20110098317-A1 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | SGMS1, SPHK1, SPHK2 | KMT2A 4026/4885MAOA 4496/4885MAOB 3521/4885 |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | KMT2A 2917/4885MAOA 1587/4885MAOB 1404/4885 |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | KMT2A 2917/4885MAOA 1587/4885MAOB 1404/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | KMT2A 1602/4885MAOA 3154/4885MAOB 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.